Logo
x

Search

Subscribe Now

Lupus

Progentec Signs a Research Collaboration with GSK to Evaluate Proteomics and Digital Health Tools for SLE

Progentec Signs a Research Collaboration with GSK to Evaluate Proteomics and Digital Health Tools for SLE

  • June 9, 2021
GSK's Benlysta (belimumab- IV) Receives EC's Approvals as the First Biologic to Treat Lupus in Children

GSK's Benlysta (belimumab- IV) Receives EC's Approvals as the First Biologic to Treat Lupus in Children

  • October 30, 2019
Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079

Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079

  • March 4, 2019
Disease of the Month – Systemic Lupus Erythematosus

    Disease of the Month – Systemic Lupus Erythematosus

    • September 18, 2024
    IASO Bio Reports the US FDA’s IND Approval of Equecabtagene Autoleucel for Two New Autoimmune Diseases

      IASO Bio Reports the US FDA’s IND Approval of Equecabtagene Autoleucel for Two New Autoimmune Diseases

      • August 12, 2024
      Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis

        Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis

        • April 18, 2024
        Viatris Collaborates with Idorsia to Develop and Commercialize Selatogrel and Cenerimod

          Viatris Collaborates with Idorsia to Develop and Commercialize Selatogrel and Cenerimod

          • February 28, 2024
          Artiva Biotherapeutics Receives the US FDA’s Fast Track Designation for AlloNK (AB-101) to Treat Lupus Nephritis

            Artiva Biotherapeutics Receives the US FDA’s Fast Track Designation for AlloNK (AB-101) to Treat Lupus Nephritis

            • February 23, 2024
            AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo

              AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo

              • February 5, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.